FY2025 EPS Estimates for TARA Boosted by Cantor Fitzgerald

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities researchers at Cantor Fitzgerald lifted their FY2025 EPS estimates for Protara Therapeutics in a note issued to investors on Monday, August 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings per share of ($1.40) for the year, up from their previous estimate of ($1.71). The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Cantor Fitzgerald also issued estimates for Protara Therapeutics’ FY2026 earnings at ($1.50) EPS.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $23.00 price target on shares of Protara Therapeutics in a report on Monday, April 28th. Jones Trading upgraded Protara Therapeutics to a “strong-buy” rating and set a $21.00 price target on the stock in a report on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $19.60.

Protara Therapeutics Price Performance

Shares of Protara Therapeutics stock opened at $3.03 on Wednesday. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48. The firm has a market capitalization of $116.90 million, a PE ratio of -1.87 and a beta of 1.42. The company’s fifty day moving average price is $3.10 and its two-hundred day moving average price is $3.58.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08.

Institutional Investors Weigh In On Protara Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC lifted its position in shares of Protara Therapeutics by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock worth $948,000 after purchasing an additional 9,553 shares in the last quarter. Barclays PLC acquired a new stake in Protara Therapeutics in the 4th quarter valued at $492,000. Dimensional Fund Advisors LP bought a new stake in Protara Therapeutics during the 4th quarter worth about $111,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Protara Therapeutics during the 4th quarter worth about $11,880,000. Finally, HBK Investments L P bought a new position in shares of Protara Therapeutics in the 4th quarter valued at about $106,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.